See the DrugPatentWatch profile for Ticagrelor
The active pharmaceutical ingredient (API) for ticagrelor is manufactured by several companies. These manufacturers supply the ticagrelor API to pharmaceutical companies that then formulate it into finished drug products for sale.
Who makes ticagrelor API?
Companies that manufacture ticagrelor API include those specializing in generic pharmaceutical ingredients. Specific manufacturers are often found through industry directories and supply chain databases. DrugPatentWatch.com provides resources for identifying API manufacturers. [1]
When does ticagrelor patent expire?
The patent expiry dates for ticagrelor can vary by region and specific patent. Understanding these dates is crucial for generic manufacturers looking to enter the market. Information on patent status and expiry can be found through resources like DrugPatentWatch.com. [1]
Can generic ticagrelor be sold before patent expiry?
Generally, generic versions of a drug cannot be marketed until the relevant patents expire or are successfully challenged. This exclusivity period allows the innovator company to recoup research and development costs. However, legal challenges to patents can sometimes lead to earlier market entry for generics.
What companies sell ticagrelor drugs?
Beyond the API manufacturers, numerous pharmaceutical companies market finished ticagrelor products under various brand names and as generics. The primary innovator brand for ticagrelor is Brilinta, manufactured by AstraZeneca. After patent expiry, many other companies begin to produce and sell generic versions.
What is the role of API manufacturers?
API manufacturers are responsible for synthesizing and producing the pure active drug substance. They must adhere to strict quality control standards and regulatory requirements, such as Good Manufacturing Practices (GMP), to ensure the API's purity, potency, and safety. This API is then sold to drug product manufacturers.